EVER CDMO: Contract Development

EVER Pharma announces the EU-wide marketing authorization of Trabectedin (in 0.25MG and 1MG vial sizes) for the treatment of advanced soft tissue sarcoma and ovarian cancer

Our products include: 

AtosibanCabazitaxelCerebrolysinDacepton (Apomorphine)DexemedetomidineDocetaxelEribulinFulvestrantMemoProveOxytocinPaclitaxelPemetrexedTestosterone EnantateTestosterone UndecanoateTachyben (Urapidil)TerlipressinTrabectedin

EVER Pharma Expands Operations with Opening of New Manufacturing Facility in Jena, Germany

Contract Manufacturing Overview

EVER Pharma has announced the approval of Testosterone Undecanoate in the European Union for the treatment of male hypogonadism. 

EVER Pharma, a fully integrated specialty pharmaceuticals company, is pleased toannounce the approval of Testosterone Enantate in the European Union for thetreatment of male hypogonadism. This condition, characterized by insufficienttestosterone production, affecting up to 10% of men globally and 40% of men aged 45.

0.25mg + 1mg

EVER Pharma, a fully integrated specialty pharmaceuticals company, announced the approval of Eribulin in the European Union. Eribulin is indicated for the treatment of locally advanced or metastatic breast cancer and unresectable liposarcoma.

PFS - 250mg/5ml

EVER Pharma is pleased to announce EU-wide approval of Bortezomib for the treatment of patients with multiple myeloma and mantle cell lymphoma

1mg/5ml + 2mg/10ml

6.75mg/0.9ml + 37.5/5ml + 75mg/10ml

2.5mg/1ml + 3.5mg/1.4ml